Please enter reference number, Or go to Order History
This medicine is indicated in type 2 diabetes (a disorder characterized by high sugar levels in blood), in combination with pioglitazone or metformin or sulphonylureas.
Bullous (pus filled injury) and exfoliative (injury characterized with shedding of skin) lesions. When taken alone it can cause dizziness; when taken with metformin it can cause tremors (shaking movements), headache, nausea (an urge to vomit), hypoglycaemia (low sugar levels); when taken with sulphonylurea it can cause tremors (shaking movements), headache, nausea (an urge to vomit), asthenia (physical weakness), hypoglycaemia (low sugar levels); when taken with a glitazone it can cause weight gain and peripheral edema (swelling of hands and feet) and with insulin it can cause headache, hypoglycaemia (low sugar levels), GI upset, chills etc.
This medicine is contraindicated in diabetic ketoacidosis (a life threatening condition in which liver breaks down fats into ketones for energy), hepatic (liver) impairment and congestive heart failure (a condition that progresses over a long time and affects the pumping of heart).
It is primarily indicated for treating Diabetes Mellitus type 2.
It is known to be a cyanopyrrolidone based derivative which is responsible for inhibition of dipeptidyl peptidase (DDP4) causing the release of insulin via beta islet cells and reduction of glucagon release via alpha islet cells of pancreas.
Dosing interval: 12 hr or 24 Hr
Maximum Dose: 100 mg, more than 100mg not recommended.
When used in monotherpay with metformin, Vildagliptin is prescribed as 50mg twice a day. When used along with sulfonylureas, vildagliptin is prescribed as 50mg once in the morning
The medication is not prescribed in patients with hepatic impairments. It is advised to closely monitor the ALT (Alanine aminotransferase) and AST (Aspartate aminotransferase) values and adjust accordingly if found to be x3 upper limit normal (ULN).
Patients with Creatinine clearence less than 50ml/min are recommended with a dose of 50mg once a day.
Doctor consultation is important before use, as human and animal research is insufficient or animals showed defects and human research hasn?t been conducted.
The data for vildagliptin if it enters breast milk; is not known. It should not be used.
End stage renal diseased patients should use this medicine with great care. Type 1 Diabetes and diabetic ketoacidosis suffering patients must also monitor therapy goals. Acute pancreatitis. Cardiovascular diseases like congestive heart faliures. Skin disorders such as blisters.
Time of onset: The drug shows a delayed onset of action when administered with meals
Tmax: 71 Liters
Bioavailability: More than 90%
Protein Binding : 9.3%
Elimination Half Life (t1/2): 1.5 Hr
Metabolism: It has been reported to primarily metabolise through liver.
Volume of Distribution (Vd): 71 Liters
Metabolite LAY151 is formed which is pharmacologically inactive.
Dawaai's intention is to make sure that it's consumers get information that is accurate, reviewed by an expert and error-free. However, the information mentioned here should not be used as a replacement for the advice of a qualified physician. The information given here is for informational purposes only, which may not cover all possible precautions, side effects, contraindications or drug interactions. Consult your doctor and discuss your queries related to any medicine or disease.